{
  "meta": {
    "data_length": 1,
    "message": "Statement id stmt:ema:alecensa:2:0 retrieved successfully",
    "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Aema%3Aalecensa%3A2%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002009,
    "timestamp_received": "2026-10-16T22:57:51.616099+00:00Z",
    "timestamp_returned": "2026-10-16T22:57:51.618108+00:00Z",
    "trace_id": "6ad3b462-bfbf-4233-bfaa-5e98234e5aea"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-08-02"
  },
  "data": [
    {
      "id": "stmt:ema:alecensa:2:0",
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the adjuvant treatment following complete tumor resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-10-20:0",
          "type": "Contribution",
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:ema:2024-06-06:0",
          "type": "Contribution",
          "description": "Indication received approval from the European Commission.",
          "date": "2024-06-06",
          "contributor": {
            "id": "agent:org:ema",
            "type": "Agent",
            "agentType": "organization",
            "name": "European Medicines Agency",
            "description": "Regulatory agency that approves medicines for use in the European Union."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema:alecensa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Alecensa (alectinib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf",
            "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Roche Registration GmbH.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Alecensa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "alectinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2017-04-11",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-06-19",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "proposition": {
        "id": "prop:vtxr:22",
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictsSensitivityTo",
        "subjectVariant": {
          "type": "CategoricalVariant",
          "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition."
        },
        "conditionQualifier": {
          "id": "dis:ncit:C2926",
          "conceptType": "Disease",
          "name": "Non-Small Cell Lung Cancer",
          "mappings": [
            {
              "relation": "exactMatch",
              "coding": {
                "id": "coding:oncotree:NSCLC",
                "code": "NSCLC",
                "name": "Non-Small Cell Lung Cancer",
                "system": "https://oncotree.mskcc.org",
                "systemVersion": "oncotree_2025_10_03",
                "iris": [
                  "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Non-Small+Cell+Lung+Cancer+%28NSCLC%29"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "solid_tumor",
              "value": true,
              "description": "Boolean value for if this tumor type is categorized as a solid tumor."
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C2926",
            "code": "C2926",
            "name": "Lung Non-Small Cell Carcinoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2926"
            ]
          }
        },
        "objectTherapeutic": {
          "id": "tx:ncit:C101790",
          "conceptType": "Therapy",
          "name": "Alectinib",
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:rxcui:1727455",
                "code": "1727455",
                "name": "alectinib",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1727455"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "coding:omop:35604657",
                "code": "35604657",
                "name": "alectinib",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/35604657"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "ALK inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ],
          "primaryCoding": {
            "id": "coding:ncit:C101790",
            "code": "C101790",
            "name": "Alectinib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "26.08e",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790"
            ]
          }
        },
        "extensions": [
          {
            "name": "biomarkers",
            "value": [
              {
                "id": "bmkr.criterion:8",
                "present": true,
                "subject": {
                  "id": "bmkr:8",
                  "type": "CategoricalVariant",
                  "name": "v::ALK",
                  "constraints": [
                    {
                      "type": "AdjacencyConstraint",
                      "orderKnown": false,
                      "adjoinedElements": [
                        {
                          "id": "gene:hgnc:427",
                          "conceptType": "Gene",
                          "name": "ALK",
                          "primaryCoding": {
                            "id": "coding:hgnc:427",
                            "code": "HGNC:427",
                            "system": "https://genenames.org",
                            "iris": [
                              "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427"
                            ]
                          },
                          "mappings": [
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ensembl:ensg00000171094",
                                "code": "ENSG00000171094",
                                "system": "https://www.ensembl.org",
                                "iris": [
                                  "https://www.ensembl.org/id/ENSG00000171094"
                                ]
                              }
                            },
                            {
                              "relation": "exactMatch",
                              "coding": {
                                "id": "coding:ncbi:238",
                                "code": "238",
                                "system": "https://www.ncbi.nlm.nih.gov/gene",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/gene/238"
                                ]
                              }
                            },
                            {
                              "relation": "relatedMatch",
                              "coding": {
                                "id": "coding:refseq:NM_004304.5",
                                "code": "NM_004304.5",
                                "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                                "iris": [
                                  "https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5"
                                ]
                              }
                            }
                          ]
                        },
                        {
                          "type": "UnspecifiedElement"
                        }
                      ]
                    }
                  ],
                  "extensions": [
                    {
                      "name": "biomarker_type",
                      "value": "Gene fusion"
                    }
                  ]
                }
              }
            ],
            "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic."
          }
        ]
      },
      "strength": {
        "id": "str:ncit:C25425",
        "conceptType": "Evidence",
        "name": "Approval",
        "mappings": [],
        "primaryCoding": {
          "id": "coding:ncit:C25425",
          "code": "C25425",
          "name": "Approval",
          "system": "https://evsexplore.semantics.cancer.gov",
          "systemVersion": "26.08e",
          "iris": [
            "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425"
          ]
        }
      },
      "extensions": [
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db."
        },
        {
          "name": "indication",
          "value": {
            "id": "ind:ema:alecensa:2",
            "type": "Indication",
            "description": "Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK-positive non-small cell lung cancer (NSCLC) at high risk of recurrence.",
            "contributions": [
              {
                "id": "ctrb:vanallenlab:2024-10-20:0",
                "type": "Contribution",
                "description": "Adding EMA approvals for use to database",
                "date": "2024-10-20",
                "contributor": {
                  "id": "agent:user:vanallenlab",
                  "type": "Agent",
                  "agentType": "contributor",
                  "name": "Van Allen lab",
                  "description": "Van Allen lab, Dana-Farber Cancer Institute"
                }
              },
              {
                "id": "ctrb:ema:2024-06-06:0",
                "type": "Contribution",
                "description": "Indication received approval from the European Commission.",
                "date": "2024-06-06",
                "contributor": {
                  "id": "agent:org:ema",
                  "type": "Agent",
                  "agentType": "organization",
                  "name": "European Medicines Agency",
                  "description": "Regulatory agency that approves medicines for use in the European Union."
                }
              }
            ],
            "reportedIn": [
              {
                "id": "doc:ema:alecensa",
                "type": "Document",
                "documentType": "Regulatory approval",
                "name": "Alecensa (alectinib) [product information]. EMA.",
                "title": null,
                "aliases": [],
                "description": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.",
                "urls": [
                  "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf",
                  "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"
                ],
                "doi": null,
                "pmid": null,
                "extensions": [
                  {
                    "name": "agent",
                    "value": {
                      "id": "agent:org:ema",
                      "type": "Agent",
                      "agentType": "organization",
                      "name": "European Medicines Agency",
                      "description": "Regulatory agency that approves medicines for use in the European Union."
                    },
                    "description": "The organization that published this document."
                  },
                  {
                    "name": "company",
                    "value": "Roche Registration GmbH.",
                    "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_brand",
                    "value": "Alecensa",
                    "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "drug_name_generic",
                    "value": "alectinib",
                    "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
                  },
                  {
                    "name": "first_publication_date",
                    "value": "2017-04-11",
                    "description": "The publication date for the initial version of this document."
                  },
                  {
                    "name": "identification_number",
                    "value": null,
                    "description": "Identification number used by the publishing organization."
                  },
                  {
                    "name": "publication_date",
                    "value": "2024-06-19",
                    "description": "The publication date for the document."
                  },
                  {
                    "name": "status",
                    "value": "Active",
                    "description": "Whether this document is Active or Deprecated within moalmanac-db."
                  }
                ]
              }
            ],
            "extensions": [
              {
                "name": "status",
                "value": "Approved",
                "description": "Current approval status."
              }
            ]
          },
          "description": "The underlying Indication supporting this Statement."
        }
      ]
    }
  ]
}